Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: An update review
Open accessThe DOI matches its Crossref record; 165 of the 167 references it cites were found in a registry or an index.
Abstract
As traditional strategies for cancer treatment, some chemotherapy agents, such as doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, and paclitaxel exert their anti-tumor effects by inducing immunogenic cell death (ICD) of tumor cells. ICD induces anti-tumor immunity through release of, or exposure to, damage-related molecular patterns (DAMPs), including high mobility group box 1 (HMGB1), calreticulin, adenosine triphosphate, and heat shock proteins. This leads to activation of tumor-specific immune responses, which can act in combination with the direct killing functions of chemotherapy drugs on cancer cells to further improve their curative effects. In this review, we highlight the molecular mechanisms underlying ICD, including those of several chemotherapeutic drugs in inducing DAMPs exposed during ICD to activate the immune system, as well as discussing the prospects for application and potential role of ICD in cancer immunotherapy, with the aim of providing valuable inspiration for future development of chemoimmunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite this, research suggests that immunogenic cell death (ICD) induced by chemotherapy, targeted therapy, and/or radiotherapy not only leads to cancer cell death but also stimulates anti-tumor immune responses through the release of tumor neoantigens and damage-associated molecular patterns (DAMPs) (Zhai et al., 2023).”
From Microphysiological systems as models for immunologically ‘cold’ tumors (2024) · cites this paper as Zhai et al., 2023
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Qu, L., Li, K., Liu, K., & Hu, W. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/4959840 · Cited by 2 · cited 1×
“mentioned that the treatment of gemcitabine and oxaliplatin combined with apatinib in gallbladder cancer will significantly increase the level of humoral immune cells, and significantly decrease the levels of sIL-2R, and sICAM-1 to effectively control the progress of the disease by improving the immune function (Qu et…”
BackgroundRetractedImmunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223 · cited 2×
“DAMPs, such as calreticulin (CRT), adenosine triphosphate (ATP), heat shock protein (HSP), and high mobility group box 1 (HMGB1) (Garg et al., 2010; Krysko et al., 2012; Boada-Romero et al., 2020).”
BackgroundCalreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216 · cited 4×
“Anthracyclines can trigger exposure to CRT, as well as HSP70 and HSP90 expression, which involves translocation of these markers to the cell surface, and thus induces anti-cancer immune responses and HMGB1 release (Obeid et al., 2007; Fucikova et al., 2011).”
BackgroundInfluentialChemotherapy drugs induce pyroptosis through caspase-3 cleavage of a gasdermin
Wang, Y., Gao, W., Shi, X., Ding, J., Liu, W., He, H., Wang, K., & Shao, F. (2017) · Nature · doi:10.1038/nature22393 · Cited by 3,199 · cited 2×
“The recovery of GSDME expression in tumor cells is helpful to enhance the function of immune cells to inhibit tumor growth (Wang et al., 2017).”
BackgroundImmunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119 · cited 2×
“ICD is a form of regulated cell death typically driven by stress (Galluzzi et al., 2017), including cell stress and cell death accompanied by exposure, active secretion, or passive release of large numbers of OPEN ACCESS”
BackgroundApetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007 · cited 5×
“In addition, they found that combination treatment of NSCLC with cisplatin and crizotinib induced ICD in vivo (Liu et al., 2019).”
BackgroundInfluentialDendritic cells in cancer immunology and immunotherapy
Wculek, S. K., Cueto, F. J., Mujal, A. M., Melero, I., Krummel, M. F., & Sancho, D. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0210-z · Cited by 2,574 · cited 1×
“Similarly, the mechanisms driving ICD have been used to produce DC-based tumor vaccines, and many clinical trials have been completed (Wculek et al., 2020).”
BackgroundMitochondria as multifaceted regulators of cell death
Bock, F. J., & Tait, S. W. G. (2020) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0173-8 · Cited by 2,450 · cited 3×
“Among them, mitochondrial outer membrane permeabilization (MOMP) plays a key role in intrinsic apoptosis by activating NF-κB (Bock and Tait, 2020).”
BackgroundNatural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101 · cited 1×
“First, ICD inducers must show superior therapeutic effect when used to treat tumors in mice with normal immune function compared with those with low immune function (Vesely et al., 2011; Garg et al., 2014; Kepp et al., 2014).”
Background
Cited by
Rha, S. Y., Oh, D.-Y., Yañez, P., Bai, Y., Ryu, M.-H., Lee, J., Rivera, F., Alves, G. V., Garrido, M., Shiu, K.-K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00515-6 · Cited by 690
Engineered Bio‐Based Hydrogels for Cancer Immunotherapy
Peng, Y., Liang, S., Meng, Q., Liu, D., Ma, K., Zhou, M., Yun, K., Rao, L., & Wang, Z. (2024) · Advanced Materials · doi:10.1002/adma.202313188 · Cited by 100
Hänggi, K., Li, J., Gangadharan, A., Liu, X., Celias, D. P., Osunmakinde, O., Keske, A., Davis, J., Ahmad, F. F., Giron, A., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.10.014 · Cited by 93
Elzoghby, A. O., Samir, O., Emam, H. E., Soliman, A., Abdelgalil, R. M., Elmorshedy, Y. M., Elkhodairy, K. A., & Nasr, M. L. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.022 · Cited by 58
“The proteasome inhibitor bortezomib (BTZ) 41 , tyrosine kinase inhibitor crizotinib 42,43 , multi-kinase inhibitor, regorafenib 44,45 , and pyruvate kinase M2 (PKM2) inhibitor shikonin (SHK) 46,47 , are among ICD inducers 48,49 .”
BackgroundRole of HIF-1α in the Responses of Tumors to Radiotherapy and Chemotherapy
Song, C. W., Kim, H., Kim, M.-S., Park, H. J., Paek, S.-H., Terezakis, S. A., & Cho, L. C. (2024) · Cancer Research and Treatment · doi:10.4143/crt.2024.255 · Cited by 65
“2) [34,35,42,72,75].”
Han, Y., Tian, X., Zhai, J., & Zhang, Z. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1363121 · Cited by 59
Self-citationReactive oxygen species of tumor microenvironment: Harnessing for immunogenic cell death
Malla, R. R., Kumari, S., Ganji, S. P., Srilatha, M., Nellipudi, H. R., & Nagaraju, G. P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189154 · Cited by 63
Nanomedicine-mediated regulated cell death in cancer immunotherapy
Sun, Y. L., Lian, T., Huang, Q., Chang, Y., Li, Y., Guo, X., Kong, W., Yang, Y., Zhang, K., Wang, P., et al. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.10.032 · Cited by 49
Immunogenic cell death: A new strategy to enhancing cancer immunotherapy
Dou, L., Fang, Y., Yang, H., Ai, G., & Shen, N. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2437918 · Cited by 46
“36,37 Mechanistically, a crucial characteristic of molecules that induce ICD is their ability to render dying cells antigenicity and adjuvanticity through stress-responsive pathways, such as endoplasmic reticulum (ER) stress, and transcriptional/translational stress.”
Metal-based immunogenic cell death inducers for cancer immunotherapy
Zou, J. X., Chang, M. R., Kuznetsov, N. A., Kee, J. X., Babak, M. V., & Ang, W. H. (2025) · Chemical Science · doi:10.1039/d4sc08495k · Cited by 48
Quercetin: A Natural Ally in Combating Breast Cancer
Zz, W., Qiu, K.-Y., Gai, Y.-J., Wu, J., Zhou, B., & Shi, Q.-F. (2025) · International Journal of Nanomedicine · doi:10.2147/ijn.s518174 · Cited by 42
“109 Quercetin enhances the effectiveness of traditional prescription medicines like cisplatin by targeting different molecular pathways.”
A “One Arrow Three Eagle” Strategy to Improve CM‐272 Primed Bladder Cancer Immunotherapy
Liu, R., Yang, J., Du, Y., Yu, X., Liao, Y., Wang, B., Yuan, K., Wang, M., Yao, Y., & Yang, P. (2023) · Advanced Materials · doi:10.1002/adma.202310522 · Cited by 42
Advancements in conventional cancer therapy combined with immunotherapy
Li, H., Han, S., Dong, C., & Liu, Z. (2024) · Oncology and Translational Medicine · doi:10.1097/ot9.0000000000000067 · Cited by 45
Emerging immunotherapies in osteosarcoma: from checkpoint blockade to cellular therapies
Han, Z., Chen, G., & Wang, D. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1579822 · Cited by 38
Inorganic Nanoparticle Functionalization Strategies in Immunotherapeutic Applications
Mao, W., & Yoo, H. S. (2024) · Biomaterials Research · doi:10.34133/bmr.0086 · Cited by 33
“One major chemotherapy actively combined with immunotherapy is cytotoxic, because it induces ICD, which can boost the adaptive immune response [205].”
BackgroundFan, J., Gillespie, K. P., Mesaros, C., & Blair, I. A. (2024) · Communications Biology · doi:10.1038/s42003-024-06930-y · Cited by 32
“Thus, translocation of CRT from the ER is a key determinant of anticancer immune responses, which has been exploited as a target mechanism for immunogenic chemotherapy 41,42,75 .”
Chen, F., Bao, R., Yang, W., Lu, Y., Guo, J., Chen, W., Li, J., Feng, K., Zhang, W., Di, L., et al. (2025) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2025.08.020 · Cited by 33
“Doxorubicin, oxaliplatin (OXA), and paclitaxel are examples of conventional chemotherapy medications that may induce immunogenic cell death (ICD), an aberrant cell death that triggers the adaptive immune system to provide an efficient anti-tumor response 283-286 .”
Role of liposomes in chemoimmunotherapy of breast cancer
Attarian, F., Hatamian, G., Nosrati, S., Oryani, M. A., Javid, H., Hashemzadeh, A., & Tarin, M. (2025) · Journal of drug targeting · doi:10.1080/1061186x.2025.2467139 · Cited by 30
“…cells, dual-targeting liposomes offer a tailored approach that maximises therapeutic impact while minimising collateral damage to healthy tissues [32,62,111–116]. the journey of chemoimmunotherapy in breast cancer is marked by challenges, but the potential for transformative outcomes is undeniable.”
InfluentialAndac-Aktas, A. B., & Calibasi‐Kocal, G. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1687556 · Cited by 29
Oncolytic virus and immunogenic cell death in cancer therapy
Cao, G., Ding, C., Dai, J., & Qiu, X. (2025) · Tumour Virus Research · doi:10.1016/j.tvr.2025.200333 · Cited by 27
“Chemotherapy-induced ICD exerts effects by synergizing tumor cell killing (via chemotherapy activity) and activating antitumor immune responses, thereby achieving better therapeutic outcomes [336].”
Opaganib (ABC294640) Induces Immunogenic Tumor Cell Death and Enhances Checkpoint Antibody Therapy
Maines, L. W., Keller, S. N., & Smith, C. D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242316901 · Cited by 26
Chen, Y., Qin, H., Li, N., Wei, Y., Lin, Y., Deng, R., Ding, H., Lv, Y., Ma, T., Li, R., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101877 · Cited by 23
“25 Therefore, our preoperative chemotherapy was preliminarily targeted to Dox.”
Sharma, S., Singh, N., Turk, A. A., Wan, I., Guttikonda, A., Dong, J. L., Zhang, X., & Opyrchal, M. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i13.1815 · Cited by 27
Immunogenic cell death inducers for cancer therapy: An emerging focus on natural products
Zhang, L., Zhang, D.-J., Shi, J.-X., Huang, M., Yu, J.-M., Chen, X.-J., Xiao, W., Zou, L., & Lu, J. (2024) · Phytomedicine · doi:10.1016/j.phymed.2024.155828 · Cited by 23
Nanostructure-reinforced multifunctional hydrogels for synergistic cancer therapy
Yousefiasl, S., Ghovvati, M., Mirshafiei, M., Hakimi, F., Azadi, A., Moezzi, S. M. I., Yuan, M., Sefat, F., Zare, I., Maleki, A., et al. (2024) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2024.216207 · Cited by 22
Qiao, J.-X., Guo, D., Tian, H., Wang, Z., Fan, Q.-Q., Tian, Y., Sun, J., Zhang, X., Zou, J., Cheng, J., et al. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101358 · Cited by 29
Andrgie, A. T., & Tsai, H. (2024) · Materials Advances · doi:10.1039/d4ma00122b · Cited by 21
Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity
Gephart, B. D., Coulter, D. W., & Solheim, J. C. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26136440 · Cited by 23
“Specifically, low-dose CPX has been shown to release damage-associated molecular patterns such as extracellular ATP and Annexin A1 in multiple in vitro studies, leading to the increased dendritic cell activation of T cell responses [17].”
Ding, R., Yang, H., Wang, J., Liu, Y., Mu, S., Wang, D., & Li, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502183 · Cited by 21
Self-citationSun, P., Huang, L., Li, Z., Yang, Y., Lu, S., Gao, N., Chen, H., Zeng, X., & Xie, Z. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.149234 · Cited by 22
Li, W., Xu, M., Cheng, M., Wei, J., Zhu, L., Deng, Y., Guo, F., Bi, F., & Liu, M. (2025) · Cancer Medicine · doi:10.1002/cam4.71065 · Cited by 21
“(ICD), a form of regulated cell death that triggers an adaptive immune response by releasing damage-associated molecular patterns (DAMPs) [18–21].”
An, M., Yan, J., Liu, B., & Liu, Q. (2026) · 癌症:英文版 · doi:10.34133/cancomm.0023 · Cited by 20
Chemotherapy-Induced Liver Injury: Unveiling Emerging Mechanisms and Exploring Mitigation Strategies
Alkabbani, M. A., Shatat, A.-A. S., Ghazy, A., & Ibrahim, K. M. (2024) · ERU Research Journal · doi:10.21608/erurj.2024.256957.1100 · Cited by 25
Current status of nanoparticle-mediated immunogenic cell death in cancer immunotherapy
Tran, T. H., & Tran, T. T. P. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113085 · Cited by 20
Recent Advances in Synthetic Isoquinoline-Based Derivatives in Drug Design
Balewski, Ł., & Kornicka, A. (2025) · Molecules · doi:10.3390/molecules30244760 · Cited by 17
Ma, S., Lu, Y., Sui, S., Yang, J.-S., Fu, B., Tan, P.-X., Chai, Y., Lv, J., Kong, L., Wu, X., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1572821 · Cited by 17
Engelen, Y., Krysko, D. V., Efimova, I., Breckpot, K., Versluis, M., Smedt, S. C. D., Lajoinie, G., & Lentacker, I. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.09.016 · Cited by 15
Application of Cyclodextrin for Cancer Immunotherapy
Wei, X., Yu, C., & Wei, H. (2023) · Molecules · doi:10.3390/molecules28145610 · Cited by 15
Microphysiological systems as models for immunologically ‘cold’ tumors
Gaebler, D., Hachey, S. J., & Hughes, C. C. W. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1389012 · Cited by 14
Yu, H., Liu, S., Yuan, Z., Huang, H., Yan, P., & Zhu, W. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117192 · Cited by 14
Reprogramming the tumor microenvironment to boost adoptive T cell therapy
Pacheco, M. F. M., & Tai, L. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1677548 · Cited by 16
“Beyond their cytotoxic reputation, these treatments also exert immunomodulatory effects; they can also awaken the immune system (15).”
InfluentialAnticarcinogenic Effects of Gold Nanoparticles and Metformin Against MCF-7 and A549 Cells
Yeşildağ, A., Kızıloğlu, H. T., Dirican, E., Erbaş, E., Gelen, V., & Kara, A. (2024) · Biological Trace Element Research · doi:10.1007/s12011-024-04090-y · Cited by 13
“Some chemotherapy drugs, including doxorubicin, cyclophosphamide, and paclitaxel, work like conventional cancer treatments by causing the tumor cells to die in an immune-mediated manner [36, 82].”
BackgroundSun, Y., Chen, W., Sun, S., Shang, H., Guan, X., & Zhang, W. (2024) · Science China Materials · doi:10.1007/s40843-024-2940-6 · Cited by 12
Chang, J., Zhao, Z., East, A. K., Bandyopadhyay, S., Jiang, Z., & Chan, J. (2025) · Chemical Science · doi:10.1039/d4sc08228a · Cited by 14
Chen, Y.-C., Mao, K., Han, D., Ma, R., Sun, T., Zhang, H., & Han, B. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1511423 · Cited by 11
Ma, C., Yu, X., Zhang, X., Su, L., Jiang, O., & Cui, R. (2025) · Oncology Letters · doi:10.3892/ol.2025.15088 · Cited by 12
“Preclinical studies have clarified how RT increases tumor immunogenicity (10,22,122).”
Elucidating DNA Damage-Dependent Immune System Activation
Deligianni, E., Papanikolaou, C., Terpos, E., & Souliotis, V. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125849 · Cited by 12
He, Z., Jing, X., Dai, X., Bao, L., Yang, X., Xiong, Y., & Li, M. (2024) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2904158 · Cited by 12
“Various re-sults also indicate that pure TAX does not effectively induce ICD [34].”
BackgroundColarusso, C., Terlizzi, M., Caprio, S. D., Falanga, A., D’Andria, E., Bianca, R. D. D. V., & Sorrentino, R. (2025) · Biomedicines · doi:10.3390/biomedicines13010203 · Cited by 11
“In this regard, a cold tumor could be rendered hot by using classical chemotherapeutics, which can induce tumor cell death, the so-called immunogenic cell death (ICD) [6], with the generation/release of alarmins that can activate pathogen recognition receptors (PRRs).”
Wu, F., Feng, X., Gao, W., Zeng, L., Xu, B., Chen, Z., Zheng, C., Hu, X., Shi-ying, X., Song, H., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.4c18469 · Cited by 8
Hsu, Y.-C., Wu, M.-C., Weng, M., Lee, Y.-T., Chou, H.-C., Lee, M., Wang, L., Sheu, J., & Chen, C. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010472 · Cited by 8
“15 17–23 Among the hundreds to thousands of compounds that have been screened for ICD induction, only a few have proved effective.”
Spatial organization of B lymphocytes and prognosis prediction in patients with gastric cancer
Tay, R. Y. K., Sachdeva, M., Ma, H., Kim, Y., Kook, M., Kim, H., Cheong, J., Hewitt, L. C., Nekolla, K., Schmidt, G., et al. (2025) · Gastric Cancer · doi:10.1007/s10120-025-01593-y · Cited by 7
“Chemotherapy agents are known to to induce immunogenic cell death in tumor cells [33].”
Safa, A., Vruzhaj, I., Gambirasi, M., & Toffoli, G. (2025) · Cancers · doi:10.3390/cancers17213506 · Cited by 7
Tan, Y., Yang, T., Jiang, S., Li, S., Cai, L., Wang, Y., Guo, Z., & Wang, X. M. (2026) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2026.113212 · Cited by 8
Optimising CAR T therapy for the treatment of solid tumors
Mobark, N., Hull, C., & Maher, J. F. (2024) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2024.2421194 · Cited by 8
Zhang, Y., Liu, C., Jin, S., Xie, L., Xiao, Q., & Yao, J. (2025) · Biomaterials Research · doi:10.34133/bmr.0232 · Cited by 7
“Although some chemotherapy drugs such as doxorubicin, mitoxantrone, and platinum-based compounds can also induce ICD [ 10 ], the clinical availability of ICD inducers remains limited.”
Li, S., Wang, S., Zhang, A., Luo, L., Song, J., Wei, G., & Fang, Z. (2024) · International Journal of Oncology · doi:10.3892/ijo.2024.5625 · Cited by 7
“DOX has been confirmed to effectively inhibit the topoisom‑ erase II α ‑mediated DNA replication by the intercalation into nuclear DNA strands in cancer cells (10,11).”
BackgroundPurnomosari, D., Nabila, B. Z., Widyarini, S., & Mustofa, M. (2025) · Medical Oncology · doi:10.1007/s12032-025-02712-6 · Cited by 6
“Additionally, T cell infiltration can also activate CD8 ⁺ T cells, leading to their differentiation into cytotoxic T lymphocytes (CTLs) and facilitating the formation of memory T cells [43].”
Studying Immunogenic Cell Death in Human Colorectal Cancer Organoids
Lisandrelli, R., Winkler, M., Trajanoski, Z., & Lamberti, G. (2025) · OncoTargets and Therapy · doi:10.2147/ott.s521346 · Cited by 6
Liu, Y.-Y., Tsai, M.-Y., Liu, T., Liu, Y., Lin, Y., Yeh, C.-H., Lin, Y.-C., & Chen, Y. (2024) · BMC Cancer · doi:10.1186/s12885-024-13066-z · Cited by 6
“Preclinical studies indicate that chemotherapy not only exerts direct cytotoxic effects but also enhances the anti-tumor response mediated by ICIs through induction of immune-mediated cell death [11–14].”
BackgroundSelf-citationMenilli, L., Milani, C., Martella, E., Tubertini, M., Tedesco, D., Guerrini, A., Baschieri, A., Costa, B., Moret, F., Ferroni, C., et al. (2025) · ACS Applied Nano Materials · doi:10.1021/acsanm.5c00589 · Cited by 5
Luo, X., Liu, Z., Fang, S., Fang, X. L., Yang, F., Zhou, F., Xu, J., Chen, Y., Liao, B., Xu, Y., et al. (2025) · Journal of Colloid and Interface Science · doi:10.1016/j.jcis.2025.138475 · Cited by 6
Ma, S., Sun, Y., Sui, S., Wu, X., Wu, X., & Li, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1787374 · Cited by 5
Yi, Q., He, S., Liao, K., Yue, Z., & Mei, L. (2024) · Nanomedicine · doi:10.2217/nnm-2023-0335 · Cited by 5
Doxorubicin induces deglycosylation of cancer cell‐intrinsic PD ‐1 by NGLY 1
Wu, D., Wu, Z., Yao, H., Yan, X., Jiao, Z., Liu, Y., Zhang, M., & Wang, D. (2024) · FEBS Letters · doi:10.1002/1873-3468.14935 · Cited by 5
Self-citationDrug Repurposing in Oncology: A Strategic Pathway to Unlocking New Therapeutic Potential
Shaik, R., Laddika, S. G., Unnisa, M., Hamza, A., Begum, S., & Sarwar, S. F. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00895-8 · Cited by 4
Zhao, H., & Dai, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1732407 · Cited by 4
“Chemotherapeutics such as anthracyclines (doxorubicin), oxaliplatin, cyclophosphamide, paclitaxel, and proteasome inhibitors (bortezomib) can trigger robust ICD via DNA damage, ER stress, and autophagy induction, releasing abundant immunostimulatory DAMPs (Zhai et al., 2023; Yerragopu et al., 2023).”
InfluentialLiu, M., Zhou, Q., Lan, B., Gan, J., & Zhang, S. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1587684 · Cited by 5
Yang, Q., Yang, G., Wu, Y., Zhang, L., Song, Z., & Yang, D. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28409 · Cited by 4
“Taking into account the previous anti-cancer evidence for the PTX-induced ICD mechanism in tumor cells [21,47], while the underlying mechanism as well as the target genes has not been systematically analyzed.”
BackgroundCRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer
Xu, C. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03208-2 · Cited by 5
“Studies have demonstrated the ability of certain chemotherapeutic agents to induce ICD, thereby boosting the immunogenicity of tumor cells, emphasizing the role of endoplasmic reticulum stress and the exposure of CRT on the tumor cell surface (Zhang et al. 2023; Zhai et al. 2023; Amiri et al. 2023).”
Effect of the immune microenvironment on prognosis in oesophageal adenocarcinoma
Peristeri, D. V., Tarazi, M., Casey, P. J., Powell, A. G. M. T., & Sultan, J. (2024) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2024.101954 · Cited by 3
Galus, Ł., Tusień-Małecka, D., Michalak, M., Kopeć, S., Kozak, K., Piejko, K., Ziętek, M., Chowaniec, Z., Stopa, B. C., Dziura, R., et al. (2025) · Współczesna Onkologia · doi:10.5114/wo.2025.150451 · Cited by 3
Ma, L., Acuff, N. V., Ptacin, J. L., Caffaro, C. E., Jose, K. M. S., Aerni, H. R., Herman, R. W., Pavlova, Y., Pena, M. J., Chen, D. B., et al. (2025) · The Journal of Immunology · doi:10.1093/jimmun/vkaf142 · Cited by 3
De-rong, W., Ma, X., Li, J., Li, C., Li, Q., & Li, F.-Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118155 · Cited by 3
Olayode, O. O., Oladosu, T. J., Abioye, A. I., Oladeji, E. O., & Ogunoye, B. T. (2025) · BMC Cancer · doi:10.1186/s12885-025-15062-3 · Cited by 3
“Such cytotoxic activity is characteristic of many established chemotherapeutic agents [48, 49].”
Shao, M., Peng, Y., & Qiu, L. (2025) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2025.124820 · Cited by 4
Tubertini, M., Menilli, L., Milani, C., Martini, C., Navacchia, M. L., Nugnes, M., Bartolini, M., Naldi, M., Tedesco, D., Martella, E., et al. (2024) · Frontiers in Chemistry · doi:10.3389/fchem.2024.1378233 · Cited by 3
“During ICD, dying cancer cells release damage-associated molecular patterns (DAMPs) and danger signals, such as calreticulin (CRT), adenosine 5 ′ -triphosphate (ATP) and the high-mobility group box 1 protein (HMGB1), which collectively recruit phagocytic cells and activate the immune system at the…”
BackgroundUsing a Natural Triterpenoid to Unlock the Antitumor Effects of Autophagy in B-Cell Lymphoma
Doonan, B. P., Radwan, F. F. Y., Banik, N. L., & Haque, A. (2025) · Biomedicines · doi:10.3390/biomedicines13020445 · Cited by 3
“While chemotherapeutic drugs induce cellular toxicity [26,27], in many cases, they are used as a general mainstay of cancer treatment, destroying cancer cells by inducing apoptosis [28], which effectively reduces the size of the tumor and prevents further tumor growth.”
Zhang, S., Jiang, N., Dang, Q., Chen, G., Wang, S., Wu, X., Bai, H., Sun, L., & Wang, X. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108796 · Cited by 2
Huang, Y., Xie, J., Wang, J., Lin, J., Chen, M., Zhao, B., & Huang, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1617905 · Cited by 2
“Red indicates patients with PD-L1-positive tumors; Blue indicates patients with PD-L1-negative tumors. immunogenic microenvironment created by drug-induced ICD can signi fi cantly enhance the ef fi cacy of ICB.”
InfluentialLenz, J., DiBona, J., Atherton, M. J., Roy–Ghanta, S., Schmidt, H., Hart, T., & Yu, J. W. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-013715 · Cited by 2
Sun, F., Lu, S., Wu, M., Yu, J., & Chen, D. (2026) · Future Oncology · doi:10.1080/14796694.2026.2652532 · Cited by 2
Liu, W., Xu, W., Liu, W., Liang, R., Tang, S., Luo, X., Liu, C., Liao, Q., Sun, H., Wang, Z., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1738966 · Cited by 4
“Chemotherapy, radiotherapy, and PDT have all been shown to induce HMGB1 release from tumor cells, which is essential for maintaining the immunogenicity of ICD (112).”
Medicinal mushrooms and the hallmarks of cancer: mechanistic insights for complementary chemotherapy
Haklai, E. (2026) · Frontiers in Cancer Control and Society · doi:10.3389/fcacs.2026.1774081 · Cited by 3
Eskandani, N. A., Ghasemzaei, M., Farani, M. R., Mirzaee, D., Hatami, A., Khosravi, A. A., Ghoreishian, S. M., & Huh, Y. S. (2026) · Nano Today · doi:10.1016/j.nantod.2026.103065 · Cited by 3
Spector, D. V., Akasov, R., Bykusov, V., Karetnikov, G. L., Zharova, A., Beloglazkina, Е., & Krasnovskaya, O. O. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.05.026 · Cited by 2
Zhong, S., Chen, W., Liu, F., Zhou, S., Yu, B., Wang, Y., Zhou, X., Wang, X., Liu, D., Zhang, Z., et al. (2026) · Advanced Science · doi:10.1002/advs.76321 · Cited by 3
“This process can release abundant damage-associated molecular patterns (DAMPs) that potentially stimulate immune surveillance [ 51 ].”
Self-citationLiang, G., Zhu, C., Sun, H., Ji, Y., & Jiang, H. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s638939 · Cited by 2
Liang, L., Ye, Z., Wu, J., Lu, H., Liu, W., Meng, L., Li, Y., & Huang, H. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.153977 · Cited by 2
Prostate Cancer Vaccines: Progress, Challenges, and Future Directions
Runtunuwu, S. V. B. E., Tallei, T. E., & Turalaki, G. L. A. (2025) · Heca Journal of Applied Sciences · doi:10.60084/hjas.v3i1.263 · Cited by 1
“In chemotherapy-based combinations, agents like mitoxantrone induce immunogenic cell death, which releases tumor antigens and enhances dendritic cell activation [204, 205].”
Li, S.-T., Li, C., Wu, X., Hua, W.-X., Dong, X.-Y., Zhang, X., Liu, X., & Kang, Y. (2025) · New Journal of Chemistry · doi:10.1039/d5nj00904a · Cited by 1
Prospect of Newcastle disease virus in clinical neurological tumour diseases
Chen, Y., Yu, Z., Ying, H., Dai, F., & Han, W. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168025 · Cited by 1
Mimura, K., & Kono, K. (2025) · FUKUSHIMA JOURNAL OF MEDICAL SCIENCE · doi:10.5387/fms.25-00009 · Cited by 1
Shaik, R., Khan, H., Salomi, M. Z., Zehra, F., Vempati, S. K., Riyaz, M., & Azeeza, S. (2025) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1177/10849785251384813 · Cited by 1
“68 The use of irradiation of DAC and bortezomib regulates heat shock protein release and proteasomal activity, moreover assigning to presentation and antigen processing.”
Clinical management of liver cancer patients with immune checkpoint inhibitors treatment
Yau, J., Chan, L. L., & Chan, S. L. (2025) · Hepatic Oncology · doi:10.1080/20450923.2025.2578079 · Cited by 1
“…intracellular content and changes the composition of cell surface during killing of tumor cells, a process referred to as immunogenic cell death [94]. combining tAce with icis thus becomes an appealing way to intensify this immune response and improve outcomes in patients with intermediate…”
Minaei, E., Wade, S. J., Penney, C., Ranson, M., Aghmesheh, M., Sluyter, R., & Vine, K. L. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202503780 · Cited by 1
Pantham, D., Argenziano, M., Christaki, F., Clemente, N., Colombo, C., Benetti, E., Pizzimenti, S., Dianzani, U., Stoppa, I., Cavalli, R., et al. (2025) · Pharmaceutics · doi:10.3390/pharmaceutics17121530 · Cited by 1
“Interestingly, it is well known that certain chemotherapeutic drugs, such as PTX, can induce the immunogenic cell death (ICD), a specialized form of apoptosis that enables immune-competent hosts to trigger a specific immune response against tumor cells [42,43].”
Zhang, Y., Zhang, B., Chen, X., Zhang, X., Liu, C., Wang, Z., & Ling, R. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1699963 · Cited by 1
Molecular Actions of Cyclophosphamide (CPA) in the Ovaries of Rats with Mammary Neoplasia
Nynca, A., Świgońska, S., Molcan, T., Petroff, B. K., & Ciereszko, R. E. (2026) · Cancer Management and Research · doi:10.2147/cmar.s557751 · Cited by 1
“10 Recently, CPA-induced ovarian dysfunction was also linked to ferroptosis-mediated cell death of granulosa cells, 7 a process driven by iron-dependent oxidative injury that culminates in plasma membrane rupture and subsequent DAMPs release.”
Suzuki, R., Watanabe, S., Shono, K., MASUDA, T., Yanai, K., Yamazaki, R., Ando, Y., Wakabayashi, T., Tanaka, S., Sekiya, T., et al. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04350-x · Cited by 2
Metadata
- Authors
- Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Zhang, Zhenyong
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2023-04-21
- Volume
- 14
- Pages
- 1152934-1152934
- ISSN
- 1663-9812 (ISSN-L)
- PMC
- PMC10160433
- OpenAlex
- W4366690216
- Cited by
- 131
- References
- 167
- Citations by year
- 2026: 36 · 2025: 51 · 2024: 38 · 2023: 6
- FWCI
- 3.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Natural Science Foundation of Liaoning Province
- National Natural Science Foundation of China
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Keywords
- immunogenic cell death, targeted therapy, HMGB1, calreticulin, ATP, heat shock proteins, tumor immunology, chemoimmunotherapy, doxorubicin, oxaliplatin, cyclophosphamide, bortezomib, paclitaxel, antitumor immunity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.